Notably, high-quality clinical evidence directly targeting DGE is scarce, with most studies conducted in models of chronic constipation, gastrointestinal motility disorders, or irritable bowel syndrome (IBS)
The physiologic properties of GLP-1 make its stable agonist a potent candidate for a novel drug target in the treatment of T2DM
This modification is intended to allow the peptide to retain the functionality of the original protein but with a longer shelf life and lower clearance
This product is neither a drug, food, nor cosmetic, and must not be misrepresented, misused, or mislabeled as such
While its not officially listed as a side effect, many people taking GLP-1 drugs like Ozempic, Wegovy, and Mounjaro report significant hair shedding
S.SessaW